🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseQuit drinking AND started sema - liver is thanking me — looking for input

Quit drinking AND started sema - liver is thanking me — looking for input

Dr.LipidDallas Fri, Mar 22, 2024 at 4:23 AM 48 replies 2,428 viewsPage 1 of 10
This thread is more than 26 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Mar 22, 2024 at 4:23 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience pathway that quiets food noise. The practical part people get wrong is that tolerance changes: less food in the stomach, faster gastric emptying of liquid relative to solids, and a smaller body mean the same two drinks land considerably harder than they used to.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

The bit I cannot resolve on my own is whether the change in tolerance is the smaller stomach, the smaller body, or something central, and whether it settles. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
36 6pam_stl, wei_SG, cory_ATX and 33 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Mar 22, 2024 at 4:52 AM#2
Dr.LipidDallas said:
Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…

Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.

Correct me if the detail matters more than I have assumed.

Last edited: Mar 22, 2024 at 5:52 AM
35 5KarenAZ_mom, zoe_NC, Dr.ObesityLA and 32 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Mar 22, 2024 at 5:21 AM#3
Dr.LipidDallas said:
Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…

This is where I part company with the consensus forming above. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

34 4MikeNYC_runner and 31 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Mar 22, 2024 at 5:50 AM#4

Taking the question as asked, rather than the general version of it. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Last edited: Mar 22, 2024 at 9:50 AM
33 3MeganSA_TX, LarryQC_SD, wanda_boise and 30 others
Reply Quote Save Share Report
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Mar 22, 2024 at 8:32 AM#5
Dr.ObesityLA said:
Agreed, and ALT falling is not the same as fibrosis improving.

This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.

32 2NurseLeah_Nash, gary_naperville, sean_dublin and 29 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register